These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Not reported||2004-004736-30||Peginterferon alfa-2a and Ribavirin Combination Therapy in Patients with HBeAg-negative Chronic HBV Infection||2009-10-15||due-trials|
|Completed, but no date||2007-005344-25||High-dose versus standard-dose weight-based ribavirin in combination with peginterferon alfa-2a for patients infected with hepatitis C virus genotype 1 or 4||bad-data|
|Ongoing||2008-006239-11||Augmenting response to entecavir using a temporary peginterferon alpha-2a add-on strategy for the treatment of HBeAg-positive chronic hepatitis B (ARES study)||not-yet-due|
|Ongoing||2009-017843-32||A multi-center randomized, open label, controlled study in primary liver transplantation comparing long term renal function and development of de novo malignancy in recipients treated with standard do...||not-yet-due|
|Ongoing||2011-002010-37||A Multi-center, Randomized, Open-label study for Induction of HBsAg decline using an add-on treatment of peginterferon alfa-2a in HBeAg-negative chronic hepatitis B patients treated with nucleos(t)ide...||not-yet-due|
|Ongoing||2011-005607-32||LOWERING VIRAL LOAD WITH NUCLEOS(T)IDE ANALOGUES PRIOR TO PEGINTERFERON ALFA-2B TREATMENT TO INCREASE SUSTAINED RESPONSE IN HBEAG-POSITIVE CHRONIC HEPATITIS B (PEGON-STUDY)||not-yet-due|
|Ongoing||2011-005636-26||Effect of Telaprevir in triple therapy for chronic hepatitis C patients on Intrahepatic immunological Mechanisms||not-yet-due|
|Ongoing||2012-001239-30||THE EFFECTS OF RECOMBINANT HUMAN INSULIN-LIKE GROWTH FACTOR-1 ON THE NUTRITIONAL STATUS IN PATIENTS WITH LIVER CIRRHOSIS: A PILOT-STUDY.||not-yet-due|
|Ongoing||2012-003181-40||Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: a multicentre randomized phase III clinical trial||not-yet-due|
|Ongoing||2013-002991-42||Effect of ASV and DCV therapy on the quality of immune status in chronic HCV patients||not-yet-due|
|Ongoing||2018-002856-34||Modifying tacrolimus related toxicity after liver transplantation. A randomized controlled trial comparing Envarsus® and Advagraf® in de novo liver transplant recipients.||not-yet-due|